On November 11, 2024, Director Sagar Lonial sold 5,000 shares of TG Therapeutics Inc (TGTX, Financial) at a price of $30.44 per share. The transaction, detailed in the SEC Filing, resulted in a total sale amount of $152,200. Following this transaction, the insider now owns 100,195 shares of the company.
TG Therapeutics Inc is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company aims to improve the quality of life and overall treatment experience for patients in these areas.
Over the past year, Sagar Lonial has sold a total of 35,933 shares and has not purchased any shares. This recent sale is part of a broader trend within TG Therapeutics Inc, where there have been 8 insider sells and no insider buys over the past year.
The stock of TG Therapeutics Inc was trading at $30.44 on the day of the sale, giving the company a market cap of approximately $4.81 billion. According to the GF Value, the intrinsic value estimate for TG Therapeutics Inc is $292.70, indicating a price-to-GF-Value ratio of 0.1. This suggests that the stock might be a possible value trap, and investors should think twice before making an investment decision.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale could provide valuable insights for current and potential investors into the insider sentiment at TG Therapeutics Inc, especially in the context of the company's valuation and stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
